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Abstract
Autoimmunity is often observed among individuals with primary immune deficiencies; however, the frequency and
role of autoimmunity in Schimke immuno-osseous dysplasia (SIOD) has not been fully assessed. SIOD, which is
caused by mutations of SMARCAL1, is a rare autosomal recessive disease with its prominent features being skeletal
dysplasia, T cell deficiency, and renal failure. We present a child with severe SIOD who developed rituximab
resistant Evans syndrome (ES). Consistent with observations in several other immunodeficiency disorders, a review
of SIOD patients showed that approximately a fifth of SIOD patients have some features of autoimmune disease.
To our best knowledge this case represents the first patient with SIOD and rituximab resistant ES and the first
study of autoimmune disease in SIOD.
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Background
The immune system has evolved to clear pathogens effi-
ciently and to tolerate self. The establishment and main-
tenance of self-tolerance is a requirement of adaptive
immunity. To accomplish this, central tolerance removes
self-reactive T cells during thymic development and per-
ipheral tolerance represses self-reactive T cells that
escape central tolerance checkpoints. Breakdown of
either central or peripheral tolerance can lead to
autoimmunity.
One such autoimmune disease is Evans syndrome
(ES), which was first described in 1951 [1]. ES is defined
by a combination (either simultaneously or sequentially)
of autoimmune hemolytic anemia (AIHA) and idiopathic
thrombocytopenic purpura (ITP) in the absence of an
identifiable underlying pathology; ES can also include
immune neutropenia [1]. Pediatric ES generally has a
chronic course of frequent exacerbations and remissions
and a mortality of 7-36%. Most patients respond to cor-
ticosteroids and/or intravenous immunoglobulins
(IVIG), but relapse is frequent. Second-line therapies
therefore include splenectomy or immunosuppressive
d r u g ss u c ha sc y c l o s p o r i n eA( C s A ) ,m y c o p h e n o l a t e
mophetil [1]. Recently, consistent with the hypothesis
that ES arises from dysregulation of B cells, the mono-
clonal antibody against the B-cell antigen CD20, rituxi-
mab, has shown much promise for treatment of ES [1].
ES may be associated with other diseases or conditions
such as systemic lupus erythematosus [2], lymphoproli-
ferative disorders [3,4], or primary immunodeficiencies
[5]. The primary immunodeficiencies, which are genetic
disorders causing partial immune system dysfunction,
are often characterised by aberrant inflammatory
responses and autoimmunity [6]. Well-studied examples
of this include autoimmune polyendocrinopathy candi-
diasis and ectodermal dystrophy (APECED), immuno-
dysregulation, polyendocrinopathy, enteropathy, and X-
linked inheritance (IPEX), autoimmune lymphoprolifera-
tive syndrome (ALPS), Wiskott-Aldrich syndrome
(WAS), Omenn syndrome, C1q deficiency, interleukin-2
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immunodeficiency [7-11].
A less well-studied immunodeficiency is Schimke
immunoosseous dysplasia (SIOD) [12]. SIOD, which was
first described by Schimke et al. in 1971 [13], is a rare
multisystem autosomal recessive disorder consisting of
facial dysmorphism, spondyloepiphyseal dysplasia lead-
ing to dysproportionate growth failure, T-cell immuno-
deficiency and nephropathy characterised by steroid
resistant nephrotic syndrome and frequently focal seg-
mental glomerulosclerosis [14,15]. Additional features
i n c l u d ei s c h e m i cc e r e b r a la ttacks, migraine-like head-
aches, hematologic abnormalities of leucopenia, anemia
and thrombocytopenia, enteropathy, hyperpigmented
skin macules, unusual hair and microdontia [15-17].
The course of the disease varies from severe with
intrauterine or early childhood onset and death in child-
hood [15,18,19] to milder disease with survival into
adulthood [15,20]. For both severe and mild disease, the
therapy is mainly symptomatic [15].
SIOD is caused by biallelic mutations in SMARCAL1
(SWI/SNF-related matrix-associated actin-dependent
regulator of chromatin, subfamily-a-like-1), which
encodes a DNA annealing helicase with homology to
the SNF2 chromatin remodelling proteins [21]. The
SMARCAL1 enzyme plays a role in the DNA stress
response and regulates gene expression [22-27].
We report a child with severe SIOD and rituximab
resistant Evans syndrome (ES) preceeding the bone mar-
row failure that can be associated with SIOD. Combined
with prior reports of other autoimmune disorders
among individuals with SIOD and upon review of our
SIOD patient database, we conclude that the T cell
immunodeficiency of SIOD compromises self-tolerance.
Materials
Patients
Patients referred to this study gave informed consent.
The study was approved by the Institutional Review
Boards of Baylor College of Medicine (Houston, TX
USA), the Hospital for Sick Children (Toronto, ON
Canada), and the University of British Columbia (Van-
couver, BC Canada). Clinical data were obtained from
questionnaires completed by the attending physician as
well as medical summaries.
Questionnaires
Physicians referring SIOD patients for molecular testing
for SIOD complete a questionnaire on the patient being
referred. Included in this questionnaire, is a question on
whether the patient has an autoimmune disorder and if
so to specify the problem, serology and therapy. In addi-
t i o n ,t h e r ea r es p e c i f i cq u e s t i o n sa s k i n gi ft h ep a t i e n t
had lymphocytopenia, neutropenia, anemia, or
thrombocytopenia as well as the nature of the cytopenia
and any effective therapies.
Results
Case
The proposita was a 4.5-year-old girl born to non-con-
sanguineous parents by caesarean section at 36 weeks of
gestation following a pregnancy complicated by intrau-
terine growth retardation. Her birth weight, length and
head circumference were 1450 g (< 3
rd percentile), 39
cm (< 3
rd percentile) and 34 cm (25
th percentile),
respectively. She did well in the newborn period with
the exception of a self-limited thrombocytopenia. Her
abdominal ultrasound detected left-sided unilateral renal
agenesis (URA), but her voiding cystography was
normal.
She was presented to our centre at the age of 3 years
with nephrotic proteinuria of 1-2 g/m
2/day without
hematuria and a blood pressure of 90/65 mmHg (diasto-
lic - 95
th percentile for height). On clinical examination,
she had a high-pitched voice, low nasal bridge, short
neck and trunk, disproportionate short stature, lumbar
lordosis, protruding abdomen and numerous pigmented
macules predominantly on her trunk. Her weight was
7.3 kg (< 3
rd percentile), and her length was 72 cm (<
3
rd percentile). She had normal neurologic development.
Initial laboratory studies showed a normal blood count
(WBC 5.2 cells per nl, HGB 13.8 g/dl, PLT 415 cells per
nl), urea (3 mmol/l), creatinine (28 μmol/l), albumin
(38.1 g/l), total protein (65.4 g/l), triglycerides (0.66
mmol/l), cholesterol (7 mmol/l), TSH (4.5 mIU/l), and
free T4 (18.1 pmol/l). She also had normal growth hor-
mone function tests. Immunological exam revealed defi-
ciency of CD4
+ and CD8
+ cells and increased CD4
+/CD8
+ ratio. Her laboratory results are summarised in
tables 1 and 2.
Because of her immunodeficiency, she developed mul-
tiple infections. At the age of 3.5 years, she had Myco-
plasma pneumoniae pneumonia with positive serology
and required hospitalization for parenteral antibiotics.
By the age of 4.5 years, she developed severe leucopenia
and recurrent protracted infections including Candida
albicans sepsis and Epstein Barr virus infection with
fever and persistently high viral load associated with a
decreased WBC.
At 4 years, she was hospitalized in status epilepticus.
Cerebral magnetic resonance imaging showed multiple
ischemic changes and narrowing of the middle cerebral
artery bilaterally. The seizures responded to phenobarbi-
tal; however, she had additional cerebral infarcts and
became triplegic with motoric aphasia.
To treat her multiple problems, we initated several
therapies. For her nephrotic syndrome, we tried a 6
week course of prednisone (60 mg/m
2/day); however,
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showed focal segmental glomerulosclerosis. For treat-
ment of her hypertension, we intially used the ACE inhi-
bitor ramipril (2.5 mg daily) and subsequently the
angiotensin receptor blocker losartan (12.5 mg daily);
her arterial blood pressure declined to the normal range
for her age and height. For treatment of her hypercho-
lesterolemia, we introduced simvastatin therapy (5 mg
daily), and her cholesterol level declined from 11 mmol/
l back to 7.1 mmol/l. To control her recurrent
Table 1 Evolution of laboratory values for the proposita
Test results at the indicated ages
Age (years) 3
§ 3.5 4 4.5 5 5.5
Test
(normal values)
WBC (cells per nl)
(4-13)
6.5 6.1 4.1 2.8 1.2 1.1
HGB (g/dl)
(11-15)
11.2 10.8 10.8 7 9.5 8.5
PLT (cells per nl)
(140-440)
435 335 63 8 11 5
urea (mmol/l)
(1.8-6.7)
3 5.2 7.1 10 6.6 10
creatinine (μmol/l)/GFR
(ml/min/1.73 m
2)
28/127 26/140 26/142 38/97 31/119 35/108
albumin (g/l)
(35-53)
40.8 43.4 43.8 38 23.3 21.3
urine- protein/creatinine (mg/mmol)
(< 20)
501 145 216 297 1321 1755
§While receiving prednisone (60 mg/m
2/day)
Table 2 Evolution of the immune and autoimmune status of the proposita
Test results at the indicated ages
Age (years) 3
§ 45
¶
Test
(normal values)
IgG (g/l)
(5.53-10.20)
7.72 12.1 1.63
IgA (g/l)
(0.33-0.91)
0.83 1.66 0.43
IgM (g/l)
(0.47-1.67)
0.97 2.19 3.49
C3 (g/l)
(0.83-2.25)
1.06 1.47 1.41
C4 (g/l)
(0.14-0.35)
0.18 0.10 0.11
ANA negative negative negative
ANCA negative negative negative
ACLA (GPL/ml)
(0.8-11)
7.0 6.3 4.3
ENA screening negative negative NM
ATA IgA (U/ml)
(0-10)
2.09 2.11 NM
CD4 absolute count x10
3/ml (35-51%) 130 (12%) 200 (13%) 70 (50%)
CD8 absolute count x10
3/ml (18-40%) 20 (1.8%) 170 (11%) 60 (44%)
CD4/CD8
(1-3%)
6.7% 1.2% 1.1%
CD19 absolute count x10
3/ml (9-35%) 0.440 (45%) 530 (35%) 0 (0%)*
§While receiving prednisone (60 mg/m
2/day)
¶Nephrotic syndrome worsened and proteinuria increased during the 5th year of life.
*After rituximab treatment.
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zole; however, the infections persisted and ultimately
she died at 5.5 years from multiorgan failure secondary
to Enterobacter cloacae sepsis.
Based on her renal failure, T-cell deficiency and dys-
morphic features, we suspected the diagnosis of SIOD.
Her skeletal radiographs also demonstrated the typical
features including flattened capital femoral epiphyses,
dysplastic acetabular fossae and marked thoracic kypho-
sis. To confirm the diagnosis molecularly, we sequenced
PCR amplification products for the coding exons of
SMARCAL1. This identified mutations c.2542G > T (p.
Glu848X) in exon 17 and c.1439C > T (p.Pro480Leu) in
exon 8; both of these mutations have been described
previously in patients with SIOD [20,21]. Confirming
compound heterozygosity, c.2542G > T was inherited
from her mother and c.1439C > T was inherited from
her father.
In addition to the above problems, the proposita
developed ITP and anemia without splenomegaly in the
latter half of her 5th year of life. The ITP was charac-
terised by severe thrombocytopenia (8 cells per nl) and
antiplatelet antibodies detectable by the immunobead
assay. A year after her mycoplasma pneumonia, two
months after onset of her ITP and before therapy with
IVIG, she developed anemia (HGB 7 g/dl, reticulocytes
3.1%, LDH 7.61 μkat/l, bilirubin 11 μmol/l); this was
accompanied by a direct antiglobulin test (DAT) that
was positive for auto-antierythrocyte antibodies. She
received one platelet transfusion and two red blood cell
transfusions shortly after the diagnosis of her ITP and
DAT-positive anemia, respectively.
Bone marrow aspirations performed at the onset of
her ITP and again 3 months later revealed reduced pla-
telet production despite normal numbers, size and mor-
phology (nuclear separation) of megakaryocytes. Each
also showed normal to hypercellular trilinear hematopo-
esis without dysplasia (myeloid precursors 47.2%, ery-
throid precursors 25%). Overall the bone marrow
morphology was compatible with immune cytopenia
and atypical for bone marrow failure. Based on this
combination of findings and her clinical features, the
proposita was diagnosed with ES.
Her ES responded poorly to standard therapies. It did
not respond to corticosteroids or to IVIG alone. How-
ever, after a month of combination therapy with predni-
sone (2 mg/kg/day) and CyA (3-4 mg/kg/day) the
platelet count and HGB level rose to the lower normal
range. Unfortunately, the thrombocytopenia reoccured
when the prednisone dose was weaned after 2 months;
the relapse, which precipitated bleeding complications,
was unresponsive to combined therapy with IVIG and
high dose steroids as well as to rituximab (4 doses of
375 mg/m
2). Throughout this time, the persistently
DAT-positive anemia progressed such that she required
8 transfusions in the last months of her life.
Ten months after presenting with thrombocytopenia
and eight months after the development of anemia, the
proposita had the onset of progressive neutropenia. She
did not have anti-neutrophil antibodies; therefore, we
interpreted this as the onset of bone marrow failure.
Concomitent with this she developed a severe coagulo-
pathy and required four platelet transfusions.
Autoimmune disease occurs commonly in SIOD patients
To ascertain whether the autoimmune disease observed
in the proposita was unique to her or part of the clinical
symptoms of SIOD, we sent questionnaires to 63 physi-
cians of SIOD patients in whom we had identified
SMARCAL1 mutations (Table 3), and 41 physicians
reported checking for autoimmune disease in their
patients. Among the 41 patients, 2 female and 6 male
patients had one or more indications of autoimmune
disease. These manifestations included thrombocytope-
nia, hemolytic anemia, enteropathy, and pericarditis with
anti-cardiolipin antibodies. In one patient with thrombo-
cytopenia, the autoimmune features resolved sponta-
neously, in another after bone marrow transplantation
and in another after splenectomy. All other patients
were successfully treated with immunosuppressive ther-
apy: steroids, cyclophosphamide or IVIG.
Discussion
As observed for SIOD [15,28,29], many other primary
immune deficiencies are characterized by infections as
well as a defect in self-tolerance. For example, APECED,
ALPS and IPEX are defined by the occurrence of auto-
immune diseases, whereas for other immune deficiencies
the autoimmune manifestations are not as prominent
[7-11]. Immunodeficiencies with less prominent autoim-
mune manifestations include common variable immuno-
deficiency [30,31], Good syndrome [32], hyper-IgM
syndrome [33], WAS [34,35], and idiopathic CD4
+ lym-
phocytopenia [36]. About 22% of individuals with com-
mon variable immunodeficiency have autoimmune
problems, and these include autoimmune cytopenias,
pernicious anemia, thyroiditis, rheumatoid arthritis and
vitiligo [30,31]. Approximately a quarter of individuals
with hyper-IgM syndrome develop an autoimmune pro-
blem such as cytopenia, nephritis, enteropathy, hepatitis,
arthritis, hypothyroidism or systemic lupus erythemato-
sus (SLE) [33]. About half of individuals with WAS have
autoimmune problems including neutropenia, arthritis,
vasculitis, uveitis, enteropathy and nephritis [34,35].
Similarly, about 20-25% of those with idiopathic CD4
+
lymphocytopenia develop an autoimmune problem such
as SLE, antiphospholipid syndrome, Grave’s disease,
colitis, thyroiditis and vitiligo [36]. Similar to these
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mune manifestations (Table 3).
The etiology of the autoimmune problems among SIOD
patients remains undefined and no consistent inflamma-
tory or serological markers have been reported [15]. As for
the immunodeficiency, however, it likely arises from a dys-
function of SMARCAL1, the enzyme mutated in SIOD
[21], within the lymphocytic lineages. Consistent with such
a cell autonomous model, SMARCAL1 is highly expressed
in the bone marrow lineages, and the limited data on one
SIOD patient suggests that bone marrow transplantation
can ameliorate the immunodeficiency [37,38].
Conclusion
In conclusion, we report the first SIOD patient with
autoimmune problems unresponsive to immunosuppres-
sion with steroids, CsA and rituximab. Additionally, we
define the frequency and spectrum of autoimmune man-
ifestions in SIOD.
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Written informed consent was obtained from the par-
ents for publication of this case report and any accom-
panying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
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Autoimmune thrombocytopenia
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episode patient died.
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Evans syndrome Steroid, CSA and rituximab resistant; patient died.
* No SMARCAL1 protein was detected in patient cells; therefore, the second allele is a null although a mutation was not detected by sequencing of the coding
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